September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Spectral-Domain Optical Coherence Tomography for Early Detection of Hydroxychloroquine Toxicity
Author Affiliations & Notes
  • Hemang K. Pandya
    Retina Service, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
    University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, United States
  • Hunter Porter
    University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, United States
  • Vinay A Shah
    Retina Service, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
    University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, United States
  • Nawajes A Mandal
    University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, United States
  • Footnotes
    Commercial Relationships   Hemang Pandya, None; Hunter Porter, None; Vinay Shah, None; Nawajes Mandal, None
  • Footnotes
    Support  NIH Grant EY022071, EY025256; Research to Prevent Blindness, USA
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 295. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Hemang K. Pandya, Hunter Porter, Vinay A Shah, Nawajes A Mandal; Spectral-Domain Optical Coherence Tomography for Early Detection of Hydroxychloroquine Toxicity. Invest. Ophthalmol. Vis. Sci. 2016;57(12):295.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Investigate and characterize retinal pathology, using Optical Coherence Tomography (OCT), in rheumatologic patients on Hydroxychloroquine (HCQ) for autoimmune disorders, such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). The drug HCQ affects and reduces lysosomal function and that will affect sphingolipid metabolism and turnover. We hypothesize sphingolipid metabolite ceramide a known factor for neuronal cell death will increase in HCQ treated retinas which in turn induce neuronal cell death throughout the retina, especially, higher sphingolipid containing retinal ganglion cells (GC) and the nerve fibers. By imaging the retina of HCQ treated RA and SLE patients we will determine inner retinal effect of HCQ.

Methods : In a prospective study we recruited 15 subjects with autoimmune diseases, such as RA and SLE, being treated with HCQ, and 25 matched healthy control subjects. In a single clinic visit, we collected patient history to determine HCQ duration and dosage. We performed OCT to determine macular volume, thickness of macular GC, inner plexiform layer (IPL) and the optic nerve retinal nerve fiber layer (RNFL).

Results : We observed a strong negative correlation between HCQ duration in months and macular volume, average macular thickness, and macular IPL and GC layer thickness, but a weak positive correlation with RNFL thickness. HCQ treated subjects had significantly reduced macular volume, and marked, albeit non-significant, reductions in IPL and GC layer thickness and average macular thickness compared to controls.

Conclusions : HCQ exposure results in reductions of inner retinal thicknesses in the macula. This identifies the need to reevaluate clinical practices for detecting retinal toxicity in patients being treated with HCQ.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×